ea0049gp65 | Developmental & Protein Endocrinology | ECE2017
Miller Bradley S.
, Moore Wayne V.
, Fechner Patricia Y.
, Van Meter Quentin L.
, Fuqua John S.
, Ng David
, Humphriss Eric
, Charlton R. William
, Bright George M.
Requirement for daily rhGH injections is a treatment burden that can compromise adherence and efficacy in patients with GHD. Somavaratan is a novel long-acting rhGH fusion protein in clinical development for pediatric and adult GHD. In a multicenter, randomized Phase 1b/2a study, somavaratan significantly improved height velocity (HV) and IGF-I in pre-pubertal children with GHD. Preliminary efficacy and safety in subjects who have completed 3 years of somavaratan treatment are...